Sirolimus – 1mg × 10 Pills [Pfizer Original]

Sirolimus – 1mg × 10 Pills | Pfizer Original Global Supply

Product Overview

Sirolimus, also known as rapamycin, is a macrolide compound originally discovered from Streptomyces hygroscopicus. It is a potent mTOR (mechanistic target of rapamycin) inhibitor with wide-ranging applications in immunosuppression, transplant medicine, anti-aging research, and oncology-related pathways.

This product is manufactured by Pfizer Inc., one of the world’s leading biopharmaceutical companies. The version offered here is part of Pfizer’s global supply chain, intended for distribution in international markets. Each box contains 10 tablets of 1mg Sirolimus, formulated to the same specifications as the U.S.-marketed Rapamune® product, though packaging and labeling may be localized for different regions.

---

Key Features & Advantages

• ✅ Original Product by Pfizer Inc. (USA)
  Manufactured under FDA and global GMP standards; not a generic or third-party product.

• ✅ Consistent Global Formulation
  Identical active ingredient and quality control across all international versions.

• ✅ mTOR Inhibitor Backed by Extensive Research
  Widely studied in fields such as immunology, oncology, and lifespan modulation.

• ✅ Used in Transplant Protocols & Cellular Pathway Studies
  Especially relevant in kidney transplant patients, T-cell proliferation inhibition, and anti-proliferative experiments.

• ✅ Secure Global Distribution
  Available to qualified institutions, distributors, and research professionals.

---

Product Specifications

• Product Name: Sirolimus Tablets 1mg

• Brand: Pfizer (Rapamune® equivalent formulation)

• Strength: 1 mg per tablet

• Contents: 10 tablets per blister pack

• Formulation: Oral tablet

• Manufacturer: Pfizer Inc. (USA)

• Packaging: Global/international version; destination-specific labeling

• Storage: Store at room temperature (15–30°C); protect from moisture

• Shelf Life: Typically 24–36 months from manufacturing date

• Classification: Originator product; not a biosimilar or generic substitute

---

Mechanism of Action

Sirolimus exerts its effect by binding to the immunophilin FKBP-12, forming a complex that inhibits the mTOR pathway, which plays a critical role in cell proliferation, metabolism, and survival. This inhibition results in:

• Suppression of T-cell and B-cell activation

• Anti-proliferative effects in vascular smooth muscle cells

• Modulation of immune signaling and inflammatory response

• Emerging potential in age-related disease models and metabolic interventions

The mTOR-inhibiting property has made Sirolimus a molecule of growing interest in academic research, longevity studies, and translational medicine.

Further reading: NIH – Sirolimus Review

---

Compliance Statement

This product is manufactured by Pfizer Inc. and distributed globally under regulated pharmaceutical export protocols. While the formulation is identical to that of the U.S. Rapamune® product, this version is labeled for international use only. It is not intended to diagnose, treat, cure, or prevent any disease in jurisdictions where prescription authorization is required. All purchasers and end-users are responsible for ensuring compliance with local laws and appropriate handling.

---

Tags / Keywords

Sirolimus Tablets, Rapamycin 1mg, Pfizer Rapamune Equivalent, mTOR Inhibitor, Immunosuppressive Agent, Anti-aging Research Compound, Transplant Medicine, FKBP-12 Binding Drug, Original Brand Sirolimus, Global Pharmaceutical Supply